Latest Conference Articles

Acalabrutinib Induces Durable Disease Control in Frontline CLL at 4 Years

August 11th 2021, 6:43pm

Pan Pacific Lymphoma Conference

Acalabrutinib, alone or in combination with obinutuzumab, demonstrated superior efficacy and an acceptable safety profile in patients with treatment-naïve chronic lymphocytic leukemia.

Loncastuximab Tesirine and Ibrutinib Combination Shows Promise in R/R DLBCL and MCL

August 11th 2021, 5:21pm

Pan Pacific Lymphoma Conference

The combination of loncastuximab tesirine-lpyl and ibrutinib displayed encouraging antitumor activity with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma and mantle cell lymphoma.

Optimal Frontline Hodgkin Lymphoma Treatment Requires Careful Consideration of Toxicities

August 11th 2021, 4:32pm

Pan Pacific Lymphoma Conference

Alison J. Moskowitz, MD, discusses recent developments made in the Hodgkin lymphoma paradigm, shared advice for optimal stratification, and spotlighted potential emerging prognostic markers that might further help to guide treatment decisions.

Ongoing Research Aims to Solidify CAR T-Cell Therapy’s Place in Non-Hodgkin Lymphoma

August 11th 2021, 3:29pm

Pan Pacific Lymphoma Conference

CAR T-cell therapy has proven to be an effective treatment option in non-Hodgkin lymphoma subtypes, such as diffuse large B-cell lymphoma, and mantle cell lymphoma.

Checkpoint Inhibitor/TKI Combos Jump RCC Treatment to Next Level

August 9th 2021, 7:23pm

School of Nursing Oncology

Five-year survival rates in renal cell carcinoma are drastically improving due to recent regulatory approvals of combination therapies involving checkpoint blockade and VEGF TKIs.

Smarter Screening, Risk Assessments Are Key to Eliminating Racial Disparities in Breast Cancer Outcomes

August 9th 2021, 7:13pm

School of Nursing Oncology

“Smarter screening” and a better understanding of the breast cancers women of color are more likely to develop are all crucial to helping these patients survive this disease at the same rates as their White counterparts.

With More At-Home Treatments Available, Importance of Medication Adherence Must Be Stressed

August 9th 2021, 6:43pm

School of Nursing Oncology

With more oral cancer therapies available, the importance of medication adherence and education must be recognized.

Knowledge of Biosimilars Becomes A Necessity in Oncology Nursing

August 9th 2021, 4:34pm

School of Nursing Oncology

Understanding the functionality and naming convention of biosimilars vs their biologic counterparts are important concepts to utilizing these agents in oncology, according to a presentation given by Teresa Knoop, MSN, RN, AOCN, during the 5th Annual School of Nursing Oncology Meeting.

Immunotherapy, Targeted Therapy, and Novel Strategies Progress Practice in GI Malignancies

August 9th 2021, 1:05pm

ASCO Direct Highlights

Data that were presented during the 2021 ASCO Annual Meeting shed light on new therapeutic strategies, and treatment considerations that are expanding the paradigms of gastrointestinal malignancies.

CDK4/6 Inhibitors Improve OS, but Sequencing Strategies Continue to Form in HR+/HER2- Breast Cancer

August 2nd 2021, 8:29pm

International Congress on the Future of Breast Cancer West

Sara A. Hurvitz, MD, highlights that although differences in overall survival and toxicity profile could inform treatment selection with CDK4/6 inhibitors, optimal sequencing with these agents remains uncertain.

Pegram Points to Progress, Ongoing Efforts in Advanced HER2+ Breast Cancer

August 2nd 2021, 8:24pm

International Congress on the Future of Breast Cancer West

Physicians treating patients with HER2-positive metastatic breast cancer have had their share of wins with treatment advances in the past few years.

Dr. Kelly on Overcoming Osimertinib Resistance in NSCLC With Bispecific Antibodies

August 1st 2021, 3:46pm

International Lung Cancer Congress

Karen L. Kelly, MD, discusses overcoming osimertinib resistance in patients with non–small cell lung cancer through the use of bispecific antibodies.

Dr. Reckamp on the Significance of ALTA in ALK+ NSCLC

August 1st 2021, 3:44pm

International Lung Cancer Congress

Karen L. Reckamp, MD, discusses the significance of the final results of the ALTA trial in patients with ALK-positive non–small cell lung cancer.

Research Efforts Seek to Unlock the Potential of PARP Inhibition in Thoracic Malignancies

August 1st 2021, 3:33pm

International Lung Cancer Congress

Ongoing studies with biomarker-selected cohorts may help to identify subsets of patients with thoracic malignancies who might confer benefit from PARP inhibitors.

Utility of Immunotherapy Keeps Evolving in Unresectable Stage III NSCLC

July 31st 2021, 6:00pm

International Lung Cancer Congress

Many checkpoint inhibitors are currently under investigation in combination with concurrent radiotherapy in stage III non–small cell lung cancer, which experts propose could have practice-changing implications.

KRAS Inhibitors Reach New Milestones in NSCLC

July 31st 2021, 5:26pm

International Lung Cancer Congress

Significant advances have been made regarding the development of KRAS G12C inhibitors in non–small cell lung cancer in recent years, explained Karen L. Reckamp, MD, who added that research regarding predictive co-mutations, acquired resistance, and combination strategies is expected to propel the utility of these agents even further.

Dr. Arcila on Choosing Between Molecular Tests in Lung Cancer

July 31st 2021, 2:00pm

International Lung Cancer Congress

Maria E. Arcila, MD, highlights important considerations for selecting among molecular diagnostic tests for patients with lung cancer.

4 Novel Drug Classes Demonstrate Early Promise for EGFR-Mutated NSCLC

July 31st 2021, 1:00pm

International Lung Cancer Congress

Osimertinib has emerged as the standard of care for patients with EGFR-mutated non–small cell lung cancer, but the need for novel agents is underscored as disease progression on the agent is inevitable.

Dr. Gandara on Incorporating MRD Testing into Lung Cancer Practice

July 31st 2021, 1:00pm

International Lung Cancer Congress

David R. Gandara, MD, discusses how minimal residual disease testing might be incorporated into lung cancer clinical practice.

Predicting the Future of Overcoming EGFR Resistance Mechanisms in NSCLC

July 31st 2021, 12:00pm

International Lung Cancer Congress

Sukhmani K. Padda, MD, discusses strategies to overcome EGFR resistance in patients with non–small cell lung cancer.